All In Biotech

Drug Trial Radar · NCT06100523

PREVenting-ENvIronment-Reprotoxic Exposures Before In Vitro Fertilization (PREVENIR-FIV)

Multidisciplinary Platform Designed to Reduce and Prevent Environmental Reprotoxic Exposures in Subfertile Couples: Assessment of the Contribution of Such Platforms on the Birth Rate After In Vitro Fertilization: Randomized Open Prospective Comparative Multicentric Study

Last checked: Nov 19, 2026Latest source record: Oct 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 4,224 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

4,224

Planned (sponsor's estimate)

Start

Jan 2024

Primary completion

Jan 2026

Study completion Jun 2028

Sponsor

Lead sponsor
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to evaluate the effectiveness of an innovative personalized management strategy adapted to the level of environmental risk, in a population of infertile couples, eligible for assisted reproductive treatment (ART) by intraconjugal In Vitro Fertilization (IVF)/ Intracytoplasmic sperm injection (ICSI). Consultation of the couple at the ARTcenter : - Prescriptions of the standard assessment of infertility to the couples eligible for ART. - Inclusion and randomization (arm A interventional vs arm B standard management) of the couples having signed the consent. - Information for each patient on a standardized online self questionnaire on environmental exposures, physical activity and stress.

Conditions

  • Infertility

Interventions

  • VisioconsulationBehavioral

    Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)

  • self-assessment questionnaireBehavioral

    self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course

  • hair samplingBiological

    hair sampling from the 2 members of the couple

  • self-assessment questionnaire on dedicated applicationBehavioral

    self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course

  • Specialized follow-upBehavioral

    proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application

  • self-assessment questionnaire for follow-upBehavioral

    self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical live birth rateTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Assitance Publique Hôpitaux de Marseille

    Marseille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.